BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 217299)

  • 1. Neurological manifestations of Fabry disease in female carriers.
    Bird TD; Lagunoff D
    Ann Neurol; 1978 Dec; 4(6):537-40. PubMed ID: 217299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease manifestations and X inactivation in heterozygous females with Fabry disease.
    Maier EM; Osterrieder S; Whybra C; Ries M; Gal A; Beck M; Roscher AA; Muntau AC
    Acta Paediatr Suppl; 2006 Apr; 95(451):30-8. PubMed ID: 16720462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fabry disease: clinic and enzymatic diagnosis of homozygous and heterozygous. New therapeutic prospects].
    Peces R; Olea T
    Nefrologia; 2002; 22(6):540-6. PubMed ID: 12516287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of multiple angiomas without any angiokeratomas in a female heterozygote with Fabry disease.
    Mirceva V; Hein R; Ring J; Möhrenschlager M
    Australas J Dermatol; 2010 Feb; 51(1):36-8. PubMed ID: 20148840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fabry disease: molecular genetics of the inherited nephropathy.
    Desnick RJ; Astrin KH; Bishop DF
    Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterozygote detection in Fabry disease utilizing multiple enzyme activities.
    Sheth KJ; Good TA; Murphy JV
    Am J Med Genet; 1981; 10(2):141-6. PubMed ID: 6274191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Angiokeratoma corporis diffusum (Fabry's disease). Update. Apropos of 2 cases].
    Larralde de Luna M; García Díaz R; Sánchez G; Ilari R; Pierini AM; Campoy C; Chamoles NH
    Med Cutan Ibero Lat Am; 1985; 13(2):129-40. PubMed ID: 2995736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical courses of two male siblings on hemodialysis for Fabry disease ].
    Itoh K; Tanaka M; Matsushita K; Miyamura N; Nishida K; Araki E; Nonoguchi H; Tomita K
    Nihon Jinzo Gakkai Shi; 2005; 47(2):121-7. PubMed ID: 15859134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neurological complications of Fabry-disease].
    Vastagh I; Constantin T; Kéri A; Rudas G; Fekete G; Bereczki D
    Ideggyogy Sz; 2011 Jan; 64(1-2):29-35. PubMed ID: 21428036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular genetics of inherited metabolic diseases--its application to the investigation of pathogenesis and the diagnosis of Fabry disease].
    Sakuraba H
    Rinsho Byori; 1994 Jun; 42(6):628-35. PubMed ID: 7914243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. X-inactivation in Fabry disease.
    Elstein D; Schachamorov E; Beeri R; Altarescu G
    Gene; 2012 Sep; 505(2):266-8. PubMed ID: 22710134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and genetic analysis of Fabry disease: report of six cases including three heterozygous females.
    Nagasaki A; Nishie W; Sato K; Oba I; Noguchi E; Akitsu H; Sawamura D; Shimizu H
    J Dermatol Sci; 2008 Oct; 52(1):61-4. PubMed ID: 18555667
    [No Abstract]   [Full Text] [Related]  

  • 13. Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes.
    Ashton-Prolla P; Tong B; Shabbeer J; Astrin KH; Eng CM; Desnick RJ
    J Investig Med; 2000 Jul; 48(4):227-35. PubMed ID: 10916280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene.
    Eng CM; Desnick RJ
    Hum Mutat; 1994; 3(2):103-11. PubMed ID: 7911050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fabry disease: molecular carrier detection and prenatal diagnosis by analysis of closely linked polymorphisms at Xq22.1.
    Caggana M; Ashley GA; Desnick RJ; Eng CM
    Am J Med Genet; 1997 Aug; 71(3):329-35. PubMed ID: 9268104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry.
    Kitagawa T; Ishige N; Suzuki K; Owada M; Ohashi T; Kobayashi M; Eto Y; Tanaka A; Mills K; Winchester B; Keutzer J
    Mol Genet Metab; 2005 Jul; 85(3):196-202. PubMed ID: 15979031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme activity for determination of presence of Fabry disease in women results in 40% false-negative results.
    Linthorst GE; Poorthuis BJ; Hollak CE
    J Am Coll Cardiol; 2008 May; 51(21):2082; author reply 2082-3. PubMed ID: 18498967
    [No Abstract]   [Full Text] [Related]  

  • 18. A carboxy-terminal truncation of human alpha-galactosidase A in a heterozygous female with Fabry disease and modification of the enzymatic activity by the carboxy-terminal domain. Increased, reduced, or absent enzyme activity depending on number of amino acid residues deleted.
    Miyamura N; Araki E; Matsuda K; Yoshimura R; Furukawa N; Tsuruzoe K; Shirotani T; Kishikawa H; Yamaguchi K; Shichiri M
    J Clin Invest; 1996 Oct; 98(8):1809-17. PubMed ID: 8878432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biochemical study of unusual cases of Fabry disease].
    Beĭer EM; Karpova EA; Udalova OV; Tsvetkova IV
    Vopr Med Khim; 1998; 44(5):494-500. PubMed ID: 9916266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional and structural nerve fiber findings in heterozygote patients with Fabry disease.
    Torvin Møller A; Winther Bach F; Feldt-Rasmussen U; Rasmussen A; Hasholt L; Lan H; Sommer C; Kølvraa S; Ballegaard M; Staehelin Jensen T
    Pain; 2009 Sep; 145(1-2):237-45. PubMed ID: 19665302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.